An acoustic neuroma diagnosis produces a specific kind of uncertainty. The tumour is benign. It will not spread to other organs. Yet it grows in one of the most functionally sensitive locations in the nervous system, where the vestibulocochlear nerve meets the brainstem, and the structures immediately adjacent to it, including the facial nerve and the cochlea, are precisely the ones patients most fear losing function of. The latest treatment for acoustic neuroma has shifted toward a much more individualised approach than was practised a generation ago. Observation is now appropriate for a substantial proportion of patients. Stereotactic radiosurgery has become the primary non-invasive treatment for tumours below three centimetres with excellent long-term control rates. Microsurgery, when indicated, now uses intraoperative neurophysiological monitoring and facial nerve mapping that were not available twenty years ago. For international patients, India offers the complete spectrum of these approaches at leading neuroscience centres, at costs 60 to 80 percent below Western equivalents.
What Acoustic Neuroma Is and Why Treatment Selection Is Complex
Acoustic neuromas, properly called vestibular schwannomas, arise from the Schwann cells of the vestibular branch of the eighth cranial nerve. They are benign, slow-growing tumours. Most are unilateral and sporadic. A small proportion are bilateral, occurring in patients with neurofibromatosis type 2 (NF2), a genetic condition requiring a different management framework.
Why Not Every Acoustic Neuroma Needs Immediate Treatment
The increasing detection of small acoustic neuromas on MRI obtained for other reasons has fundamentally changed the treatment landscape. Many tumours diagnosed incidentally are small, growing slowly, and causing minimal symptoms. Observation with serial MRI is now a guideline-supported strategy for these patients, avoiding unnecessary treatment and its potential side effects.
Growth rates vary considerably. A retrospective study of Gamma Knife radiosurgery patients found that tumour volume grew, remained the same, or decreased in 10.4, 25.5, and 64.2 percent of patients respectively over a median 153-month follow-up period. This data reflects the natural history of acoustic neuroma: many tumours grow slowly, some remain stable for years, and some regress spontaneously.
The decision between observation, radiosurgery, and microsurgery depends on tumour size, growth rate on serial imaging, the patient's current hearing status, age, general health, and treatment preferences. A multidisciplinary approach is essential to optimise treatment outcomes.
The Latest Treatment Options for Acoustic Neuroma
Option 1: Observation and Active Surveillance
Active surveillance is the appropriate initial strategy for many patients with newly diagnosed acoustic neuroma, particularly those with small tumours, good hearing, and no symptoms attributable to mass effect.
Surveillance involves annual gadolinium-enhanced MRI for the first two to three years to determine the growth rate, followed by less frequent imaging if the tumour is stable. The MRI scanning interval is extended to every two to three years in stable tumours. If growth is confirmed on serial imaging, treatment is initiated.
Audiometric testing accompanies MRI surveillance to track hearing function over time. If hearing declines significantly during observation, the treatment decision changes, because preserving hearing that has already been lost is no longer possible.
Option 2: Stereotactic Radiosurgery: The Latest First-Line Treatment for Most Patients
Stereotactic radiosurgery is the primary non-invasive treatment modality for acoustic neuroma and has become the most commonly used first-line intervention for tumours that are growing but remain below three centimetres.
SRS delivers precisely targeted high-dose radiation to the tumour in one to five sessions, without any incision, without general anaesthesia in most cases, and without a hospital stay beyond an overnight observation. The radiation does not remove the tumour. It halts its growth by damaging the ability of tumour cells to divide, while sparing surrounding structures through the precision of dose delivery.
The long-term control data for SRS in acoustic neuroma is now well-established. A meta-analysis reporting the outcomes of 1,409 patients confirmed tumour control achieved in 96.1 percent. A large LINAC and CyberKnife series of 335 patients reported clinical tumour control of 98 percent at two years, 89 percent at five years, and 88 percent at ten years. Gamma Knife SRS achieves actuarial tumour control rates of 95.3 percent at three years, 94.3 percent at five years, 87.7 percent at ten years, and 86.6 percent at fifteen years per Park et al, with significantly reduced long-term control in tumours exceeding eight cubic centimetres in volume.
For hearing preservation specifically, patients with serviceable hearing prior to SRS should be informed that there is a high probability above 75 percent of hearing preservation at two years, a moderately high probability above 50 percent at five years, and a moderately low probability above 25 percent at ten years, per the June 2025 CNS guideline update on hearing preservation in vestibular schwannoma. At five years, serviceable hearing preservation after SRS is approximately 68.4 percent in a major Gamma Knife series.
The main platform delivering SRS for acoustic neuroma is the Gamma Knife, which is purpose-built for intracranial radiosurgery and provides the most established evidence base for acoustic neuroma treatment. CyberKnife and LINAC-based systems provide equivalent tumour control outcomes in comparative series.
SRS is appropriate for tumours up to approximately three centimetres in maximum diameter that are not causing acute brainstem compression or disabling imbalance from mass effect. For larger tumours or those causing significant brainstem shift, microsurgery is preferred.
Option 3: Microsurgical Resection When Surgery Is the Right Choice
Microsurgery remains the only treatment that physically removes the tumour and is the most appropriate choice for patients with large tumours (above three centimetres), those with significant mass effect on the brainstem, those with rapidly progressive hearing loss in a young patient where long-term hearing preservation is a priority, and patients with NF2-related bilateral tumours requiring staged resection.
Three surgical approaches are used for acoustic neuroma resection:
-
Retrosigmoid (suboccipital) approach: A craniotomy behind the ear that provides excellent access to the tumour in the cerebellopontine angle while preserving the possibility of hearing preservation. It is the most flexible approach in terms of tumour size and provides the widest field for large tumours. Hearing preservation rates with retrosigmoid microsurgery are higher than with translabyrinthine surgery.
-
Translabyrinthine approach: Access is gained through the inner ear structures including the semicircular canals. It sacrifices hearing in the operated ear but provides the most direct route to the internal auditory canal and is preferred when hearing is already non-functional or when the surgeon is seeking the widest facial nerve exposure with the lowest risk of facial weakness.
-
Middle cranial fossa approach: Used for small tumours confined to the internal auditory canal in patients with excellent baseline hearing. It provides the best hearing preservation rates but is limited to intracanalicular and very small tumours.
-
Intraoperative facial nerve monitoring is mandatory during acoustic neuroma surgery, allowing the surgeon to preserve the facial nerve throughout the procedure by detecting proximity to the nerve in real time. Intraoperative neurophysiology and facial nerve mapping represent the most important advance in microsurgery for acoustic neuroma over the past two decades.
For patients considering surgery for acoustic neuroma at India's leading neurosurgical centres, Dr. K. R. Suresh Bapu at the Institute of Neurosciences, SIMS Hospital Chennai , has specific documented expertise in total excision of cerebellopontine angle tumours with preservation of the facial nerve. For more on his surgical approach, read: How Dr. K. R. Suresh Bapu Approaches Complex Brain Tumor Treatment Cases
Option 4: Fractionated Stereotactic Radiotherapy (FSRT)
For tumours immediately adjacent to the cochlea or brainstem where single-session SRS dose constraints cannot be met safely, fractionated SRT delivers the treatment in five to thirty small fractions over one to six weeks. This fractionated approach allows higher total doses to be delivered with greater sparing of adjacent critical structures, and is used for larger tumours or those in particularly sensitive locations that are not amenable to single-session radiosurgery.
Hearing Rehabilitation After Acoustic Neuroma Treatment
Regardless of which treatment is chosen, hearing changes are a common and clinically significant consequence that requires proactive management.
When Hearing Is Lost
For patients who lose useful hearing in the treated ear, two primary rehabilitation options restore functional hearing:
-
CROS hearing aid (Contralateral Routing of Signals): Routes sound from the deaf ear to the hearing ear via a wireless transmitter and receiver. It does not restore true binaural hearing but significantly improves awareness of sound from the deaf side. It is non-surgical and reversible.
-
Bone-anchored hearing aid (BAHA): A titanium implant osseointegrated into the skull behind the ear conducts sound vibration directly through bone to the functioning cochlea on the opposite side. The BAHA achieves better speech perception in noise than the CROS aid and is the rehabilitation of choice for patients with profound single-sided deafness.
-
Auditory brainstem implants (ABI) are available for NF2 patients who lose all cochlear function bilaterally and cannot benefit from conventional hearing aids. ABI electrodes are placed directly on the cochlear nucleus in the brainstem during tumour surgery.
Acoustic Neuroma Treatment in India: What International Patients Access
India's leading neuroscience centres offer the complete acoustic neuroma treatment spectrum: active surveillance with MRI, Gamma Knife and CyberKnife SRS, LINAC-based FSRT, and microsurgery using all three approaches with intraoperative facial nerve monitoring. This breadth of capability is available at NABH and JCI-accredited hospitals, with neurosurgeons and radiation oncologists who have high-volume experience in each modality.
Cost Comparison
| Treatment | India cost | USA / UK equivalent |
|---|---|---|
| Gamma Knife / CyberKnife SRS | Rs. 1,50,000 to Rs. 2,50,000 (USD 1,800 to USD 3,000) | USD 10,000 to USD 30,000 |
| Microsurgical resection | Rs. 2,00,000 to Rs. 4,50,000 (USD 2,400 to USD 5,400) | USD 30,000 to USD 80,000 |
| MRI surveillance (annual) | Rs. 8,000 to Rs. 15,000 (USD 100 to USD 180) | USD 1,500 to USD 3,000 |
| BAHA implant | Rs. 1,50,000 to Rs. 2,50,000 (USD 1,800 to USD 3,000) | USD 8,000 to USD 20,000 |
SIMS Hospital, read: No Open Surgery Required: Advanced Endovascular Options for Brain Aneurysms
International Patient Stay Planning
-
For SRS: 5 to 7 days total, covering pre-treatment MRI and planning, the procedure itself (day case or one-night stay), and post-treatment observation before travel.
-
For microsurgery: 14 to 21 days, covering pre-operative assessment, surgery, hospital stay of five to seven days, wound check, and audiological review before clearance for long-haul travel.
How Karetrip Connects International Patients to the Right Acoustic Neuroma Programme in India
Treatment selection for acoustic neuroma is one of the most nuanced decisions in benign tumour management, and the right answer depends on tumour size, hearing status, growth rate, and patient age and preference. Karetrip reviews each patient's MRI, audiogram, and clinical history before recommending a centre and specialist, confirming that the proposed team has specific experience in the approach most appropriate for the patient's tumour.
From pre-travel imaging review and medical visa coordination, through accommodation near the treating hospital and discharge planning for follow-up audiology and MRI surveillance at home, Karetrip manages the complete international patient journey for acoustic neuroma treatment in India.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward an expert acoustic neuroma assessment at India's leading neuroscience centres.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Acoustic neuroma management requires specialist evaluation by a qualified neurosurgeon and otolaryngologist. Consult your treating team before making any treatment decision.